BAIAP2L1

Across TCGA pan-cancer cohorts, BAIAP2L1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BAIAP2L1 data layer compared with 26 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BAIAP2L1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BAIAP2L1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where BAIAP2L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.715	0.939	<.001	90	view →
LUAD	DFS	Tertile	II,III,IV	0.224	1.000	.003	21	view →
HNSC	DFS	Tertile	II,III,IV	0.983	0.858	.004	18	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.350	.006	8	view →
PDAC	DFS	Median	IV	0.203	0.678	.021	3	view →
GBM	DFS	Quartile	All	0.860	0.524	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BAIAP2L1–CCRCC (OS)

Open the CCRCC breakdown →